This report analyzes the Global Market for Nanomedicine in Millions of US$ by the following Application Areas: Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials, and Others. Annual forecasts are provided for the period of 2006 through 2015. The report profiles 263 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Acusphere, Inc., Advion Biosciences, Inc., Agilent Technologies, Inc., AMAG Pharmaceuticals, Inc., Amgen, Inc., Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Nanotope, Inc., Tego BioSciences Corporation, BioForce Nanosciences, Inc., BioSante Pharmaceuticals, Inc., Crucell N.V., Elan Corporation Plc, Elan Drug Technologies, Ensysce Biosciences, Inc., Enzon Pharmaceuticals, Inc., eSpin Technologies, Inc., Flamel Technologies S.A., Johnson & Johnson, Life Technologies Corporation, Merck & Co., Inc., Nanobiotix, NanoCarrier Co., Ltd., Nanospectra Biosciences, Inc, Nanosphere, Inc., Nanosys, Inc., Nektar Therapeutics, Novavax, Inc., Oxonica Plc, Par Pharmaceutical Companies, Inc, pSivida Limited, Starpharma Holdings Limited, Dendritic Nanotechnologies, Inc., Starpharma Pty. Ltd., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

 
TABLE OF CONTENTS

NANOMEDICINE	  		MCP-1482
A GLOBAL STRATEGIC BUSINESS REPORT


                                               CONTENTS 


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-3
       Quantitative Techniques & Analytics                              I-3
      Product Definitions and Scope of Study                            I-3
       Drug Delivery                                                    I-4
       In Vitro Diagnostics                                             I-4
       In Vivo Imaging                                                  I-4
       Biomaterials                                                     I-4
       Others                                                           I-4


 II. EXECUTIVE SUMMARY

  1. INDUSTRY OVERVIEW                                                  II-1
      Introduction                                                      II-1
      Current and Future Analysis                                       II-1
      Industry Drivers                                                  II-1
      Industry Challenges                                               II-2
      Developing World Ready to Adopt Nanomedicine in a Major Way       II-3
       India                                                            II-3
       China                                                            II-4
       Japan                                                            II-4
       Taiwan                                                           II-4
      Nanotechnology Based Medical Products                             II-4
       Table 1: Global Nanomedicine Market (2007): Percentage
       Breakdown of Number of Nano-Based Products by Application
       Area - Drug Delivery, Biomaterials, In Vivo Imaging, and
       Others (includes corresponding Graph/Chart)                      II-5
       Nanotechnology Based Drug Delivery Products                      II-5
        Table 2: Global Nanomedicine Market (2007): Percentage
        Breakdown of Number of Nano-Based Drug Delivery Products by
        Category - Liposomes, Nanocristals, Virosomes, and Others
        (includes corresponding Graph/Chart)                            II-5
       Nanomedicine Patent Filings                                      II-6
        Table 3: Global Nanomedicine Market (1993-2003): Percentage
        Breakdown of Nanomedicine Patents by Application Area - Drug
        Delivery, In Vitro Diagnostics, Imaging, Biomaterials, and
        Others (includes corresponding Graph/Chart)                     II-6

        Table 4: Global Nanomedicine Market (1993-2003): Percentage
        Breakdown of Patents by Country - US, Germany, Japan, and
        Others (includes corresponding Graph/Chart)                     II-6

  2. TRENDS & ISSUES                                                    II-7
      Nanomedicine - The Future Direction                               II-7
      Transforming Healthcare Sector Generating Demand for Nanomedicine II-7
      Nanobiotechnology - A Promising Area                              II-8
      High Demand for Tiny Healthcare Devices                           II-8
      Research in Nanomedicine Continues to Surge                       II-9
      Nanotechnology in Healthcare to Sustain R&D Funding               II-9
      Nanomedicine Clinical Pipeline to Sustain the Momentum            II-10
      Nanotechnology Gaining Ground in Fast Growing Drug Delivery
       Market                                                           II-10
      Nanotechnology - Generating More Enthusiasm Among Entrants        II-11
      Demand for Supplies and Devices to Grow Rapidly                   II-12
      Nanomedicine Needs Analysis of Ethical Implications               II-12
      Nanotechnology-based Drug Delivery Market on an Upbeat            II-12
      Nanotechnology Opens Up New Frontiers in Drug Discovery           II-12
      Nanotechnology Raises Hope for Tuberculosis Treatment             II-13
      Demand for Nano-Based Medical Products to Rise Significantly      II-13
      Medical Nanorobotics to Raise the Standards                       II-13
      Nanomedicine - A Useful Element in Surgical Procedures            II-14
      Nano-based Diagnosis and Medical Imaging Helps Treatment of
       Critical Diseases                                                II-14
      More Efficient Nanoparticles Could be Made Possible by
       Modeling Software                                                II-15
      Major Issues Daunting Nanomedicine Sector                         II-16

  3. PRODUCT/TECHNOLOGY OVERVIEW                                        II-17
      Nanomedicine - A Primer                                           II-17
       Nanopores                                                        II-17
       Radio-Controlled Biomolecules                                    II-17
       Quantum Dots                                                     II-18
       Nanotubes                                                        II-18
       Fullerenes                                                       II-19
       Nanoshells                                                       II-19
       Nanoprobes                                                       II-19
       Nanoparticles                                                    II-19
        Ceramic Nanoparticles                                           II-20
        Solid Lipid Nanoparticles                                       II-20
       Nanocapsules                                                     II-21
       Dendrimers                                                       II-21
       Liposomes                                                        II-21
       Micelles                                                         II-21
       Nanosuspensions                                                  II-22
       Liquid Crystals                                                  II-22
       Hydrogels                                                        II-22
       Polymeric Nanoparticles                                          II-22
       Molecularly Imprinted Polymers                                   II-23

  4. APPLICATIONS                                                       II-24
      Drug Delivery                                                     II-24
       Targeted Nanodrug Delivery & Release                             II-25
       Active and Passive Targeting Mechanisms in Drug Delivery         II-25
       Sustained and Pulsatile Release Mechanisms in Drug Delivery      II-25
      In Vitro Diagnostics                                              II-26
      In Vivo Imaging                                                   II-26
      Biomaterials                                                      II-26
      Others                                                            II-26
       Drugs and Therapy                                                II-26
       Active Medical Implants                                          II-26
      Oncology                                                          II-26
       Key Applications in Cancer Therapy                               II-27
        Advanced Imaging, Early-Stage Detection, and Targeting          II-27
        In-vivo Imaging                                                 II-28
        Effective Tracking of Process Efficiency                        II-28
        Advancing Bioinformatics and Proteomics Research                II-28
        Carbon Nanotubes in Cancer Treatment                            II-28
      Regenerative Medicine                                             II-28
      Futuristic Applications                                           II-29
       Bio-molecular Motors                                             II-29
       Genetic and Tissue Engineering                                   II-29
        External Tissue Products                                        II-29
        Internal Tissue Implants                                        II-30
        Dental and Bone Replacement                                     II-30
        Protein and Gene Analysis                                       II-30
        Nanorobot Therapeutics                                          II-30
       Lab-on-a-Chip Techniques                                         II-31
       Medical Diagnostic Sensors                                       II-32
       Nano Medical Devices - From Surgical Tools to Contact Lenses     II-32
       Nanoengineered Prosthetics                                       II-32
       Nanotubes - Potential Drug Delivery Vehicles                     II-32

  5. NANOTECHNOLOGY - AN OVERVIEW                                       II-33
      Building Blocks of Nanotechnology Used, Components and Final
       End-Use Products                                                 II-33
      Global Nanotechnology Market                                      II-33
       Table 5: Global Nanotechnology Market (2008 & 2009):
       Percentage Breakdown of Revenues by End-Use Segments -
       Chemicals, Automotive, Aerospace & Defense, Semi-Conductors &
       Electronics, Nanomedicine and Others (includes corresponding
       Graph/Chart)                                                     II-34
      Commercial Applications at an Embryonic Stage                     II-34
       Recent Commercial Applications of Nanotechnology                 II-35
      Nanotech Players - Germany Tops Europe While China Leads Asia -
       Pacific                                                          II-36
       Table 6: Nanotech Companies in Europe (2007): Number of
       Players in Major Regional Markets - Germany, United Kingdom,
       Switzerland, France, and Sweden (includes corresponding
       Graph/Chart)                                                     II-36

       Table 7: Nanotech Companies in Asia-Pacific (2007): Number of
       Players in Major Regional Markets - China, South Korea,
       Japan, Australia, and Taiwan (includes corresponding
       Graph/Chart)                                                     II-37
      Nanotech Funding by Regional Governments                          II-37
       Table 8: Nanotech Funding by Regional Governments (2008):
       Leading National Markets Ranked by Funding in US$ Million for
       United States, Japan, Russia, Germany and China (includes
       corresponding Graph/Chart)                                       II-37

  6. TECHNOLOGICAL DEVELOPMENTS                                         II-38
      German Scientists Develop Nanoparticle-Driven Gene Transfer
       Method                                                           II-38
      Oxford Sees Progress in its Novel DNA Sequencing Technology
       Project                                                          II-38
      Philips Releases First 3D Imaging Findings                        II-38
      Researchers in University of Pennsylvania Invent Novel Carbon
       Nanopipette                                                      II-39
      UCLA Scientists Develop Localized and Controlled Drug Delivery
       Method                                                           II-39
      Minerva Makes New Discovery in Cancer Treatment                   II-40
      NanoBio Releases Positive Data with NB-002                        II-40
      NanoBio Receives Positive Pre-Clinical Results with Intranasal
       Influenza Vaccine                                                II-41
      Abraxis Announces Interim Results of Abraxane® for Metastatic
       Breast Cancer                                                    II-41
      Abraxis Reveals Positive Data with Abraxane® and Gemzar®          II-41
      BioDelivery Commences Clinical Study with Bioral® Amphotericin B  II-42
      NanoCarrier Develops Protein Nanoencapsulation Technology         II-42
      Flamel Releases Positive Preliminary Data from FT-105 Phase I
       Study                                                            II-42
      Abraxis Releases Positive Pre-Clinical Data with nab™
       Technology Platform and SPARC Expression in Cancer Treatment     II-43
      American Scientists Develop Unique Nano-Based Drug Delivery
       System                                                           II-43
      Researchers at University of Queensland Focus to Develop Novel
       Nano-based Diagnostics for Cancer Detection                      II-43
      Indian Researchers Synthesize Polymeric Nanocurcumin for
       Cancer Therapy                                                   II-44
      Researchers Mull on Using Nanoparticles to Develop Anti-Tumor
       Vaccines                                                         II-44
      Nanomedicine Creates New Avenues for Regeneration of Nerve Cells  II-44
      University of Illinois Develop Enhanced Biomimetic Membranes      II-45
      Johns Hopkins Faculty develop Nanoparticle-Embedded Microcapsules II-45
      Max Planck Research Team Develops Gold Nanoparticles              II-45
      Nanotechnology based Panacea for Facial Wrinkles                  II-45

  7. PRODUCT INTRODUCTIONS/INNOVATIONS                                  II-46
      Starpharma Holdings Releases the NanoJuice™ Transfection Kit      II-46
      Telomolecular Introduces Nano-Based Aging Solution                II-46
      CytoViva® Unveils Advanced Nanotechnology Research Tool           II-46
      eBioscience Introduces eFluor™ Brand                              II-47
      eBioscience Launches eFluor™ Nanocrystals                         II-47
      BioForce Nanosciences Unveils Surface Patterning Service          II-47
      Eastman Kodak Unveils KODAK X-SIGHT Imaging Agents                II-47
      Biomet Launches NanoTite Dental Implant                           II-47
      Deerac Introduces Equator HTS/2 Liquid Handling Solution          II-48
      IMEC Develops Functionalized Magnetic Nanoparticles               II-48
      Ivoclar Vivadent Introduces New Version of Tetric Flow            II-48
      Calando to Begin Human Clinical Trials for siRNA-based
       Therapeutic Drug for Cancer                                      II-49
      Dabur Pharma Launches Nano-Based Drug Delivery System             II-49

  8. RECENT INDUSTRY ACTIVITY                                           II-50
      APR Acquires New Drug Delivery Platform                           II-50
      Merck Inks Merger Agreement with Schering-Plough                  II-50
      Nanobiotix to Collaborate with SonoDrugs Project Consortium       II-50
      Liquidia and Abbott to Jointly Develop siRNA Therapeutics         II-50
      Pro-Tect Acquires Medivices’ Nanotechnology Method                II-51
      APR to Create Dedicated Nanotechnology Unit                       II-51
      Agilent Takes Over Nano Instruments                               II-51
      Veridex Acquires Immunicon                                        II-51
      Thermo Fisher Takes Over nAscent                                  II-52
      Labcyte and Deerac Fluidics Combine Operations                    II-52
      Invitrogen and Applied Biosystems Merge to Form Life Technologies II-52
      Insert Therapeutics Merges with Calando Pharmaceuticals           II-52
      Capsulution Nanoscience and NanoDel Technologies Merge            II-53
      BioForce Forms Collaboration with UAlbany NanoCollege             II-53
      Advion and Bruker Daltonik Enter into Joint Marketing Agreement   II-53
      Midatech Group Inks Agreement with MonoSol Rx                     II-53
      Advion Signs Co-Marketing Agreement with Agilent Technologies     II-54
      Abraxis Inks Deal to Re-Acquire US Rights to Abraxane             II-54
      NanoKTN and Bio Nano to Develop Nanomedicine                      II-54
      Evolved Machines Inks License Contract with Nanosys               II-54
      Abraxis Bags European Commission Approval to Market Abraxane      II-55
      Nanogen Eyes European Molecular Diagnostics Market                II-55
      Abraxis Receives Approval for Marketing ABRAXANE in Korea and
       China                                                            II-55
      BioForce Receives MIT Validation for Nano eNabler Molecular
       Printer                                                          II-55
      Oxonica and Becton, Dickinson and Co. Sign Strategic Deal         II-55
      Nanogen Sells Royalties to DRI Capital                            II-56
      Nanogen Signs Deal with Thermo Fisher                             II-56
      Midatech Establishes New Nanotechnology Subsidiary                II-56
      Nanogen and HX Diagnostics Extend Collaboration                   II-57
      CytImmune Joins Hands with University of Maryland                 II-57
      Abraxis Inks Licensing Deal with Japan’s Taiho                    II-57
      Abraxis Files Marketing Application for Abraxane in Japan         II-58
      BioForce Secures State Funding for ViriChip™                      II-58
      Capsulution and Advanced Materials Ink Patent License Deal        II-58
      Midatech Bags US Grant on Patent Application                      II-59
      Nanobiotix Wins European Patent for Activable Particles           II-59
      Nanotherapeutics Submits IND Application for NanoDOX ™ Hydrogel   II-59
      Nanobiotix to Focus on Development of Diagnostics for Tropical
       Diseases                                                         II-59
      Ceres to Develop Novel Nanotechnology Products                    II-60
      Batist to Commence Production of Nanotechnology- Based Bandage    II-60
      Unidym Creates Spin-Off Unit                                      II-60
      Avanti Creates Dedicated Targeted Drug Delivery Company           II-61
      Hill-Rom Chooses Anti-Microbial Technology of NanoHorizons        II-61
      Advion Acquires NanoTek                                           II-61
      Pioneer Surgical Acquires Angstrom Medica                         II-61
      Arrowhead Acquires C Sixty                                        II-62
      Veritek Completes Acquisition of Omni-Lite E-Form                 II-62
      Wyeth Extends Collaboration with Ablynx                           II-62
      Starpharma Inks Agreement with Stiefel                            II-62
      Nanosys Signs Collaboration Deal with Bruker Daltonics            II-63
      Abraxis Selects Green Cross to Commercialize Abraxane in Korea    II-63
      Abraxis Signs Deal to Partner California NanoSystems Institute    II-63
      BioForce Nanosciences Inflates Clientele Base for Nano
       eNabler™ System                                                  II-64
      Xidex Bags Contract to Make Carbon Nanotube Sources for
       Electron Microscopes                                             II-64
      Novartis Extends Deal with Ablynx                                 II-64
      BioSante Inks License Agreement with Medical Aesthetics           II-64
      NanoImaging Launches Imaging Services Unit                        II-65
      Midatech Inaugurates cGMP Standard Nanoparticles Production
       Facility                                                         II-65
      Abraxis Announces Dedicated Proprietary Biotechnology Business    II-65
      Eksigent Signs Distribution Deal in Brazil                        II-66
      NanoVic Establishes Two Nano-bio Companies                        II-66
      Veeco Signs Collaboration Deal with Leica                         II-66
      NanoViricides Inks CRADA with USDoD Agency                        II-67
      Rexahn Wins Maryland Industrial Partnerships Funding              II-67
      Azaya Therapeutics Gains Patent for Nanotech-Based Cancer
       Treatment Platform                                               II-67
      Flamel Inks Deal with Wyeth Pharmaceuticals                       II-67
      Flamel Signs Deal with Merck Serono                               II-67
      NanoChip® 400 Platform of Nanogen Now a GSA Schedule Product      II-68
      Nanogen Bags Canadian Funding for Veterinary and Bio-Terror
       Diagnostics Development Project                                  II-68
      Nanogen Signs Deal in Australia for Schizophrenia Markers         II-68
      Wyeth Wins FDA Approval for New Labeling for Rapamune             II-69
      Arrowhead Infuses Capital into Tego                               II-69
      GSK Extends Collaboration with Exelixis                           II-69
      Oncologix Collaborates with Dendritic Nanotechnologies to
       Redesign its Oncosphere Product                                  II-70
      Abraxis Signs Licensing Contract in India                         II-70
      Abraxis Receives Australian TGA’s Acceptance to Review
       Marketing Application for Abraxane®                              II-70
      Nanotherapeutics and National Cancer Institute Sign CRADA         II-71
      Relisys and Cinvention Extend Licensing Agreement                 II-71
      Lumera Extends Collaboration Pact with Medical University of
       South Carolina                                                   II-71

  9. FOCUS ON SELECT PLAYERS                                            II-72
      Abraxis BioScience, Inc. (US)                                     II-72
      Acusphere, Inc. (US)                                              II-72
      Advion Biosciences, Inc. (US)                                     II-72
      Agilent Technologies, Inc. (US)                                   II-72
      AMAG Pharmaceuticals, Inc. (US)                                   II-73
      Amgen, Inc. (US)                                                  II-73
      Arrowhead Research Corporation (US)                               II-73
       Calando Pharmaceuticals, Inc. (US)                               II-74
       Nanotope, Inc. (US)                                              II-74
       Tego BioSciences Corporation (US)                                II-74
      BioForce Nanosciences, Inc. (US)                                  II-74
      BioSante Pharmaceuticals, Inc. (US)                               II-75
      Crucell N.V. (The Netherlands)                                    II-75
      Elan Corporation Plc (Ireland)                                    II-75
       Elan Drug Technologies (Ireland)                                 II-76
      Ensysce Biosciences, Inc. (US)                                    II-76
      Enzon Pharmaceuticals, Inc. (US)                                  II-76
      eSpin Technologies, Inc. (US)                                     II-76
      Flamel Technologies S.A. (France)                                 II-77
      Johnson & Johnson (US)                                            II-77
      Life Technologies Corporation (US)                                II-77
      Merck & Co., Inc. (US)                                            II-78
      Nanobiotix (France)                                               II-78
      NanoCarrier Co., Ltd. (Japan)                                     II-79
      Nanospectra Biosciences, Inc. (US)                                II-79
      Nanosphere, Inc. (US)                                             II-79
      Nanosys, Inc. (US)                                                II-79
      Nektar Therapeutics (US)                                          II-80
      Novavax, Inc. (US)                                                II-80
      Oxonica Plc (UK)                                                  II-80
      Par Pharmaceutical Companies, Inc. (US)                           II-80
      pSivida Limited (Australia)                                       II-81
      Starpharma Holdings Limited (Australia)                           II-81
       Dendritic Nanotechnologies, Inc. (US)                            II-81
       Starpharma Pty. Ltd. (Australia)                                 II-81
      Wyeth Pharmaceuticals, Inc. (US)                                  II-82

  10. GLOBAL MARKET PERSPECTIVE                                         II-83
      Table 9: World Recent Past, Current & Future Analysis for
      Nanomedicine Market by Application Area - Drug Delivery, In
      Vitro Diagnostics, In Vivo Imaging, Biomaterials and Other
      Applications Independently Analyzed with Annual Revenues in
      US$ Million for the Years 2006 through 2015 (includes
      corresponding Graph/Chart)                                        II-83

      Table 10: World 10-Year Perspective for Nanomedicine Market by
      Application Area - Percentage Breakdown of Revenues for Drug
      Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials
      and Other Applications for the Years 2006, 2009 and 2015
      (includes corresponding Graph/Chart)                              II-84


III. COMPETITIVE LANDSCAPE

  Total Companies Profiled: 263 (including Divisions/Subsidiaries - 269)

  ------------------------------------------
  Region/Country                     Players
  ------------------------------------------
  The United States                    178
  Canada	                         9
  Japan	                                 1
  Europe	                        58
     France	                         6
     Germany	                        17
     The United Kingdom	                10
     Spain	                         6 
     Rest of Europe	                19 
  Asia-Pacific (Excluding Japan)        15
  Middle East	                         8 
  ------------------------------------------